FLT3 and acute myeloid leukemia: NPM1mut-AML with an FLT3 mutation should receive midostaurin in addition to standard chemotherapy followed by consolidation with allo-HSCT per the RATIFY trial, especially with high FLT3-ITD allelic ratio (>0.5), as studies have shown that allo-transplant at first complete remission (CR1) improved both relapse-free and overall survival irrespective of the FLT3 allelic ratio [49,50].